Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
Top Cited Papers
Open Access
- 24 February 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (6) , 6041-6063
Abstract
The discovery of elironrasib (RMC-6291) represents a significant breakthrough in targeting the previously deemed undruggable GTP-bound, active KRASG12C. To target the active state of RAS (RAS(ON)) directly, we have employed an innovative tri-complex inhibitor (TCI) modality involving formation of a complex with an inhibitor, the intracellular chaperone protein CypA, and the target protein KRASG12C in its GTP-bound form. The resulting tri-complex inhibits oncogenic signaling, inducing tumor regressions across various preclinical models of KRASG12C mutant human cancers. Here we report structure-guided medicinal chemistry efforts that led to the discovery of elironrasib, a potent, orally bioavailable, RAS(ON) G12C-selective, covalent, tri-complex inhibitor. The investigational agent elironrasib is currently undergoing phase 1 clinical trials (NCT05462717, NCT06128551, NCT06162221), with preliminary data indicating clinical activity in patients who had progressed on first-generation inactive state-selective KRASG12C inhibitors.Keywords
This publication has 111 references indexed in Scilit:
- Design Principles for Balancing Lipophilicity and Permeability in beyond Rule of 5 SpaceChemMedChem, 2023
- Recent progress in covalent warheads for in vivo targeting of endogenous proteinsBioorganic & Medicinal Chemistry, 2021
- Prediction of Chameleonic EfficiencyChemMedChem, 2021
- Solution Conformations Explain the Chameleonic Behaviour of Macrocyclic DrugsChemistry – A European Journal, 2020
- Molecular inflation, attrition and the rule of fiveAdvanced Drug Delivery Reviews, 2016
- Improving on Nature: Making a Cyclic Heptapeptide Orally BioavailableAngewandte Chemie International Edition, 2014
- Revealing Atropisomer Axial Chirality in Drug DiscoveryChemMedChem, 2011
- The Challenge of Atropisomerism in Drug DiscoveryAngewandte Chemie International Edition, 2009
- Design, synthesis, and evaluation of novel kazusamycin A derivatives as potent antitumor agentsBioorganic & Medicinal Chemistry Letters, 2006
- Cyclosporins: Recent Developments in Biosynthesis, Pharmacology and Biology, and Clinical Applications1997